NASDAQ: GYRE - Gyre Therapeutics, Inc.

半年間の収益性: +3.06%

プロモーションスケジュール Gyre Therapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.

さらに詳しく
The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

EBITDA 0.0049
EV/EBITDA 212.18
IPO date 2006-04-12
ISIN US4037831033
Industry Biotechnology
P/BV 91.75
P/E 285.47
P/S 74.68
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.0141
Див.доход ао 0
Дивиденд ао 25.05
Сайт https://www.gyretx.com
Цена ао 16.79
Число акций ао 0.06583 млрд
1日あたりの価格変動: -5.18% (13.13)
週ごとの価格変動: +11.76% (11.14)
月ごとの料金変更: +6.41% (11.7)
3ヶ月間の価格変動: -2.43% (12.76)
半年間の価格変動: +3.06% (12.08)
年間の価格変動: -51.54% (25.69)
3年間の価格推移: +516.34% (2.02)
5年間の価格推移: +12.36% (11.08)
10年間の価格推移: 0% (12.45)
年初からの価格変動: +11.96% (11.12)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 17.22 1
P/BV 140.07 1
P/E 0 0
EV/EBITDA 16.55 6
合計: 2.13

効率

名前 意味 学年
ROA, % -79.74 0
ROE, % 587.14 10
合計: 5

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0.5 5
合計: 2.22

義務

名前 意味 学年
Debt/EBITDA 0.0035 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 1890733.33 10
収益性 Ebitda, % -347.89 0
収益性 EPS, % 123.83 10
合計: 6
さらに詳しく

機関 音量 共有, %
Renaissance Technologies, LLC 39379 0.1
Geode Capital Management, LLC 17250 0.05
Vanguard Group Inc 13793 0.04
Blackrock Inc. 10250 0.03
Citigroup Inc. 7748 0.02
Morgan Stanley 6516 0.02
Kynam Capital Management, LP 6004 0.02
Northern Trust Corporation 5761 0.02
State Street Corporation 4840 0.01
Nantahala Capital Management, LLC 4520 0.01

ETF 共有, % 年間の利益率, % 配当金, %
iShares Morningstar Small Cap Value ETF 0.00477 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.00477 199.14 2.50476
iShares Morningstar Small-Cap ETF 0.00416 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.00416 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00411 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.00411 590.83 0.72598

スーパーバイザー 役職 支払い 生年
Dr. Han Ying Ph.D. CEO & Director 10.5k 1966 (59 年)
Mr. Songjiang Ma President & Director N/A 1956 (69 年)
Ms. Ruoyu Chen Chief Financial Officer 121.35k 1971 (54 年)
Mr. Weiguo Ye Chief Operating Officer 274.62k 1978 (47 年)
Ms. Seline E. Miller CPA Senior Vice President of Finance N/A 1970 (55 年)

住所: United States, San Diego. CA, 12770 High Bluff Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.gyretx.com